|Daily Range||$135.04 - $136.25|
|52-Week Range||$125.02 - $156.77|
|Dividend (Yield)||$0.00 (1.3%)|
|Average Daily Volume||38,917|
|Current FY EPS||$7.79|
News & Commentary
Regeneron's sales and income are soaring and new drug launches could lead to even better results in the future.
While there's much talk about further controlling the food supply and being a greedy corporation, few are considering the potential environmental benefits behind Monsanto's bid for Syngenta.
There's plenty of reasons why the seed and chemicals giant can break out of its funk.
Animal health stocks are out-performing human health ones. Don't be afraid to take a bite -- there are some great opportunities in this space.
Isis Pharmaceuticals' stock was off to the races again in May. Find out what two factors led shares notably higher last month, and whether this momentum can continue.
The field where the Internet of Things is likely to have the biggest impact is often the field no one associates with it: biotech.
Looking for healthcare stocks with solid dividends that should keep flowing? These three stand out as winners.
Prices for cancer medications are soaring.
Three Motley Fool experts tell readers what upcoming FDA decisions have caught their eye.
Biogen Idec, Regeneron, and Amgen Inc. may be better bets than Gilead Sciences.